Abstracts Archive - Page 816 of 2607 - ACR Meeting Abstracts

Abstract Number: 1663 • ACR Convergence 2021
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
Abstract Number: 1664 • ACR Convergence 2021
Changes in Physical Function Were Not Associated with Clinically Important Changes in Muscle Strength or Physical Performance over Time – A Cohort Study
Rafaela Espírito Santo¹, Joshua Baker², Jordana Silva³, Lidiane Filippin⁴, Juliana Portes¹, Claiton Brenol¹, Rafael Chakr⁵ and Ricardo Xavier⁶, ¹Hospital de Clínicas de Porto Alegre, Laboratório de Doenças Autoimunes, Serviço de Reumatologia, Porto Alegre, Brazil; Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Porto Alegre, Brazil, ²University of Pennsylvania, Philadelphia, PA, ³Institute of musculoskeletal medicine, University Hospital Munster, Munster, Germany, ⁴Universidade La Salle, Canoas, Brazil, ⁵Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: The Health Assessment Questionnaire Disability Index (HAQ) is negatively associated with muscle strength by handgrip test and positively associated with physical performance by timed…
Abstract Number: 1665 • ACR Convergence 2021
Physical Activity Moderates Inflammatory Gene Expression in Rheumatoid Arthritis
Sarah Patterson¹, Shenghuan Sun², Dmitry Rychkov², Alexandra Tsitsiklis², Paula Hayakawa Serpa², Patricia Katz², Charles Langelier² and Marina Sirota², ¹University of California San Francisco, Pacifica, CA, ²University of California San Francisco, San Francisco, CA
Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…
Abstract Number: 1666 • ACR Convergence 2021
Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthritis Disease Activity
Patricia Katz¹, Sarah Patterson², Mary Nakamura³, Aric Prather¹, Laura Trupin⁴, Stephanie Rush¹ and Katie Stone¹, ¹University of California San Francisco, San Francisco, CA, ²University of California San Francisco, Pacifica, CA, ³UCSF/SFVAHCS, San Francisco, CA, ⁴UC San Francisco, San Francisco, CA
Background/Purpose: A large proportion of individuals with rheumatoid arthritis (RA), between 45%-70%, report sleep problems. Despite frequent reports of sleep problems, however, studies using objective…
Abstract Number: 1667 • ACR Convergence 2021
Efficacy of Plasma Phosphoethanolamine as a Biomarker for Rheumatoid Arthritis-associated Depression
Yusuke Miwa¹, Yoshiaki Ohashi², Hajime Tomatsu³ and Yuko Mitamura⁴, ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²HMT Biomedical Inc., Yokohama, Japan, ³HMT Biomedical Inc., Chuo, Japan, ⁴Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Shinagawa-ku, Japan
Background/Purpose: The odds of patients with rheumatoid arthritis (RA) experiencing depression is 1.42 (95% CI: 1.3–1.5; approximately 15% of patients) compared with healthy individuals. Diagnosis…
Abstract Number: 1668 • ACR Convergence 2021
Unmet Need in Early Rheumatoid Arthritis – Why Do Some Patients Do Badly Despite Modern Treat-to-target Strategies of Care? Results from the Scottish Early RA (SERA) Inception Cohort
Elizabeth Clarke¹, Claire Wood¹, Alistair Tindell¹, Kay Graham¹, Alasdair McIntosh², Fraser Morton² and Duncan Porter³, ¹NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³University of Glasgow, Bearsden, United Kingdom
Background/Purpose: ‘Treat to target’ strategies of care have significantly improved outcomes in people with early rheumatoid arthritis; nonetheless, a significant proportion of patients have impaired…
Abstract Number: 1669 • ACR Convergence 2021
Minimal Erosive Volume Needed for Radiographic Identification of Erosions in the Metacarpophalangeal Joints in Rheumatoid Arthritis. a Comparative Analysis of High Resolution Peripheral Quantitative Computed Tomography and Conventional Radiography
Rasmus Klose-Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, Bente L. Langdahl, Anna Zejden, Jesper Thygensen, Kresten Krarup Keller and Ellen-Margrethe Hauge, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The purpose of this study was to estimate the minimal erosive volume identified by High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT) needed in order to…
Abstract Number: 1670 • ACR Convergence 2021
Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam², Ben Ponvilawan³, Pitchaporn Yingchoncharoen³ and Jerapas Thongpiya⁴, ¹Cleveland Clinic, Cleveland Heights, OH, ²Mount Auburn Hospital, Boston, MA, ³Mahidol University, Bangkok, Thailand, ⁴Mahdiol University, Bangkok, Thailand
Background/Purpose: Recent experimental studies have suggested that systemic inflammatory response could lead to impairment of lower esophageal function, resulting in gastroesophageal reflux disease (GERD). Epidemiologic…
Abstract Number: 1671 • ACR Convergence 2021
COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City
Jonah Levine¹, Vivian Bykerk², Lindsay Lally¹, Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: COVID-19 in patients with rheumatoid arthritis (RA) is poorly understood. A recent study of mostly men with RA demonstrated increased COVID-19 risk in RA…
Abstract Number: 1672 • ACR Convergence 2021
Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA
Susan Bartlett¹, Dana DiRenzo², Michelle Jones³ and Clifton Bingham², ¹McGill University, Montréal, QC, Canada, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Rheumatic diseases (RD) are chronic conditions that require potent immunosuppressants to control systemic inflammation. Fears associated with increased vulnerability from being on immunosuppressants plus…
Abstract Number: 1673 • ACR Convergence 2021
Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions
Orit Schieir¹, Susan Bartlett², Marie-France Valois², Louis Bessette³, Gilles Boire⁴, Glen Hazlewood⁵, Carol Hitchon⁶, Edward Keystone⁷, Janet Pope⁸, Diane Tin⁹, Carter Thorne¹⁰, Vivian Bykerk¹¹ and CATCH Investigators¹², ¹Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: During the COVID-19 pandemic, Canadians adults with RA faced considerable uncertainty due to greater risk of infection, hospitalization, changing access to RA medications, and…
Abstract Number: 1674 • ACR Convergence 2021
Effectiveness and Safety of Tofacitinib in Canadian Patients with RA: Primary Results from a Multicenter, Observational Study
Boulos Haraoui¹, Majed Khraishi², Denis Choquette¹, Larissa Lisnevskaia³, Michelle Teo⁴, Cassandra Kinch⁵, Corina Galos⁶, Patrice Roy⁵, David Gruben⁷, John C Woolcott⁸, Julie Vaillancourt⁹, John Sampalis¹⁰ and Edward Keystone¹¹, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada, ³Oshawa Clinic, Oshawa, ON, Canada, ⁴Penticton Regional Hospital, Penticton, BC, Canada, ⁵Pfizer Canada ULC, Kirkland, QC, Canada, ⁶Pfizer Canada ULC, Kirkland, SK, Canada, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA, ⁹JSS Medical Research, Montréal, QC, Canada, ¹⁰McGill University and JSS Medical Research, Montréal, QC, Canada, ¹¹Keystone Consulting Enterprises Inc., Toronto, ON, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor (JAKi) for the treatment of RA. CANTORAL is the first large-scale, national, observational study assessing effectiveness and…
Abstract Number: 1675 • ACR Convergence 2021
Risk of Malignancy in Patients Treated with Tofacitinib: Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Farzin Khosrow-Khavar, Rishi Desai, Hemin Lee, Su Been Lee and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Initial reports from “ORAL Surveillance” post-marketing safety trial have suggested that tofacitinib, in comparison with tumor necrosis factor inhibitors (TNFI), may be associated with…
Abstract Number: 1676 • ACR Convergence 2021
Safety of Baricitinib in Japanese Patients with Rheumatoid Arthritis (RA): The 2020 Interim Report from All-case Post Marketing Surveillance in Clinical Practice
Takao Fujii¹, Tatsuya Atsumi², Nami Okamoto³, Nobunori Takahashi⁴, Naoto Tamura⁵, Atsuo Nakajima⁶, Ayako Nakajima⁷, Hiroaki Matsuno⁸, Naoto Tsujimoto⁹, Atsushi Nishikawa¹⁰, Taeko Ishii¹⁰, Tsutomu Takeuchi¹¹, Masataka Kuwana¹² and Michiaki Takagi¹³, ¹Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, ²Hokkaido University, Sapporo, Japan, ³Osaka Medical College, Takatsuki-city, Japan, ⁴Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁵Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁶Ueno Touseki Clinic, Fukuoka, Japan, ⁷Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ⁸Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁹Eli Lilly Japan K.K.,, Kobe, Japan, ¹⁰Eli Lilly Japan K.K., Kobe, Japan, ¹¹Div. Rheumatology, Keio University, Tokyo, Japan, ¹²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹³Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan
Background/Purpose: An all-case post marketing surveillance (PMS) of baricitinib, that started in Sep 2017, collects safety and effectiveness for the first 24 weeks of treatment…
Abstract Number: 1677 • ACR Convergence 2021
Effects of Biological-DMARDs on the Serum Low-density Lipoprotein (LDL) / High-density Lipoprotein (HDL) – Cholesterol Ratio in Patients with Rheumatoid Arthritis
Yusuke Miwa¹ and Yuko Mitamura², ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Shinagawa-ku, Japan
Background/Purpose: Rheumatoid arthritis (RA) and dyslipidemia are associated with inflammation. Although the low-density lipoprotein cholesterol (LDL-C) is normal range, the high-density lipoprotein cholesterol (HDL-C) is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].